Search Results - "FUSI, Alberto"

Vasculogenic mimicry in small cell lung cancer by Williamson, Stuart C., Metcalf, Robert L., Trapani, Francesca, Mohan, Sumitra, Antonello, Jenny, Abbott, Benjamin, Leong, Hui Sun, Chester, Christopher P. E., Simms, Nicole, Polanski, Radoslaw, Nonaka, Daisuke, Priest, Lynsey, Fusi, Alberto, Carlsson, Fredrika, Carlsson, Anders, Hendrix, Mary J. C., Seftor, Richard E. B., Seftor, Elisabeth A., Rothwell, Dominic G., Hughes, Andrew, Hicks, James, Miller, Crispin, Kuhn, Peter, Brady, Ged, Simpson, Kathryn L., Blackhall, Fiona H., Dive, Caroline

“…Small cell lung cancer (SCLC) is characterized by prevalent circulating tumour cells (CTCs), early metastasis and poor prognosis. We show that SCLC patients…”
Get full text

Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer by POLANSKI, Radostaw, HODGKINSON, Cassandra L, SMITH, Paul D, BLACKHALL, Fiona, DIVE, Caroline, MORROW, Christopher J, FUSI, Alberto, NONAKA, Daisuke, PRIEST, Lynsey, KELLY, Paul, TRAPANI, Francesca, BISHOP, Paul W, WHITE, Anne, CRITCHLOW, Susan E

“…The monocarboxylate transporter 1 (MCT1) inhibitor, AZD3965, is undergoing phase I evaluation in the United Kingdom. AZD3965 is proposed, via lactate transport…”
Get full text

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma by Girotti, Maria Romina, Gremel, Gabriela, Lee, Rebecca, Galvani, Elena, Rothwell, Dominic, Viros, Amaya, Mandal, Amit Kumar, Lim, Kok Haw Jonathan, Saturno, Grazia, Furney, Simon J, Baenke, Franziska, Pedersen, Malin, Rogan, Jane, Swan, Jacqueline, Smith, Matthew, Fusi, Alberto, Oudit, Deemesh, Dhomen, Nathalie, Brady, Ged, Lorigan, Paul, Dive, Caroline, Marais, Richard

“…Targeted therapies and immunotherapies have transformed melanoma care, extending median survival from ∼9 to over 25 months, but nevertheless most patients…”
Get more information

Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients by Liu, Zhian, Fusi, Alberto, Klopocki, Eva, Schmittel, Alexander, Tinhofer, Ingeborg, Nonnenmacher, Anika, Keilholz, Ulrich

“…A limitation of positive selection strategies to enrich for circulating tumor cells (CTCs) is that there might be CTCs with insufficient expression of the…”
Get full text

PD-L1 expression as a potential predictive biomarker by Fusi, Alberto, Festino, Lucia, Botti, Gerado, Masucci, Giuseppe, Melero, Ignacio, Lorigan, Paul, Ascierto, Paolo A

“…[...]the use of PD-L1 as a biomarker is problematic and other biomarkers are emerging as potentially more important predictive factors of response…”
Get full text

Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity by Dalgleish, Angus G, Mudan, Satvinder, Fusi, Alberto

“…The use of checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab) has revolutionised the treatment of metastatic melanoma. However still more than the…”
Get full text

Expression of the Stem Cell Markers Nestin and CD133 on Circulating Melanoma Cells by Fusi, Alberto, Reichelt, Uta, Busse, Antonia, Ochsenreither, Sebastian, Rietz, Anika, Maisel, Markus, Keilholz, Ulrich

“…Different molecular markers have been identified for melanoma-initiating cells including CD133 and nestin. Assuming that metastasis requires a dissemination of…”
Get full text

Expression of chemokine receptors on circulating tumor cells in patients with solid tumors by Fusi, Alberto, Liu, Zhian, Kümmerlen, Verena, Nonnemacher, Anika, Jeske, Judith, Keilholz, Ulrich

“…The study was performed to investigate the expression of chemokine receptors (CR) on circulating tumor cells (CTC), which may be of importance for…”
Get full text

Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway by Gross, Alexander, Niemetz-Rahn, Annett, Nonnenmacher, Anika, Tucholski, Johannes, Keilholz, Ulrich, Fusi, Alberto

“…Data regarding the expression of epidermal growth factor receptor (EGFR) in melanoma and its role in the tumor biology are conflicting. In BRAF V600-mutant…”
Get full text

Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma by Busse, Antonia, Asemissen, Anne Marie, Nonnenmacher, Anika, Braun, Floriane, Ochsenreither, Sebastian, Stather, David, Fusi, Alberto, Schmittel, Alexander, Miller, Kurt, Thiel, Eckhard, Keilholz, Ulrich

“…Abstract Background Tyrosine kinase inhibitors (TKI) such as sorafenib have substantially improved the prognosis of metastatic renal cell carcinoma (mRCC)…”
Get full text

In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype by Hotz, Birgit, Keilholz, Ulrich, Fusi, Alberto, Buhr, Heinz J., Hotz, Hubert G.

“…Background Targeting the epidermal growth factor receptor (EGFR) pathway is an important approach for a variety of tumors. This study assessed the effect of…”
Get full text

Serum Apolipoprotein E and Other Inflammatory Markers Can Identify Non-Responding Patients to a Dendritic Cell Vaccine by Leeman, Hayley, Kaminska, Elwira, Green, Deborah, Bodman-Smith, Mark, Gravett, Andrew, Bodman-Smith, Katherine, Copier, John, Coulton, Gary, Fusi, Alberto, Dalgleish, Angus G.

“…BACKGROUND: Despite the majority of patients do not gain any benefit from dendritic cells (DC) vaccines, this approach has occasionally given rise to dramatic…”
Get full text

Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine by Liu, Zhian, Fusi, Alberto, Schmittel, Alexander, Tinhofer, Ingeborg, Schneider, Achim, Keilholz, Ulrich

“…For breast cancer patients, treatment decisions based on the molecular profile of the primary tumor have been used for many years. In Her2-overexpressing…”
Get full text

Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populations by Ochsenreither, Sebastian, Fusi, Alberto, Busse, Antonia, Nagorsen, Dirk, Schrama, David, Becker, Jürgen, Thiel, Eckhard, Keilholz, Ulrich

“…Quantification of T-cell receptor (TCR) chain families can be utilized for detection of clonal T-cell populations. Besides southern blotting and antibody-based…”
Get full text

Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patients by Ochsenreither, Sebastian, Fusi, Alberto, Wojtke, Susanne, Busse, Antonia, Nüssler, Natascha C, Thiel, Eckhard, Keilholz, Ulrich, Nagorsen, Dirk

“…Several immunotherapeutic approaches rely on antigen-specific T-cells. Restrictions in the T-cell receptor (TCR) repertoire were reported as indicator of…”
Get full text

The importance for immunoregulation for long-term cancer control by Fusi, Alberto, Dalgleish, Angus

“…Immune checkpoint blockades have recently emerged as a breakthrough treatment for solid tumors showing high response rates and long durability. In melanoma,…”
Get full text

Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer by Howell, Matthew, Lee, Rebecca, Bowyer, Samantha, Fusi, Alberto, Lorigan, Paul

“…Highlights • Most immune related toxicities are low grade and easily manageable with treatment protocols. • It is important to recognise and manage side…”
Get full text

A phase II study to evaluate the safety and efficacy of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma: Final results of the IMM-101-015 trial by Fusi, Alberto, Gupta, Avinash, Lorigan, Paul, Smith, Peter L, Bowles, Mike

“…9554 Background: IMM-101 is a suspension of heat-killed whole cell Mycobacterium obuense (NCTC 13365), which enhances the innate immune response and dendritic…”
Get full text

Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors by Schütte, Moritz, Risch, Thomas, Abdavi-Azar, Nilofar, Boehnke, Karsten, Schumacher, Dirk, Keil, Marlen, Yildiriman, Reha, Jandrasits, Christine, Borodina, Tatiana, Amstislavskiy, Vyacheslav, Worth, Catherine L., Schweiger, Caroline, Liebs, Sandra, Lange, Martin, Warnatz, Hans- Jörg, Butcher, Lee M., Barrett, James E., Sultan, Marc, Wierling, Christoph, Golob-Schwarzl, Nicole, Lax, Sigurd, Uranitsch, Stefan, Becker, Michael, Welte, Yvonne, Regan, Joseph Lewis, Silvestrov, Maxine, Kehler, Inge, Fusi, Alberto, Kessler, Thomas, Herwig, Ralf, Landegren, Ulf, Wienke, Dirk, Nilsson, Mats, Velasco, Juan A., Garin-Chesa, Pilar, Reinhard, Christoph, Beck, Stephan, Schäfer, Reinhold, Regenbrecht, Christian R. A., Henderson, David, Lange, Bodo, Haybaeck, Johannes, Keilholz, Ulrich, Hoffmann, Jens, Lehrach, Hans, Yaspo, Marie-Laure

“…Colorectal carcinoma represents a heterogeneous entity, with only a fraction of the tumours responding to available therapies, requiring a better molecular…”
Get full text

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium by Amaria, Rodabe N, Menzies, Alexander M, Burton, Elizabeth M, Scolyer, Richard A, Tetzlaff, Michael T, Antdbacka, Robert, Ariyan, Charlotte, Bassett, Roland, Carter, Brett, Daud, Adil, Faries, Mark, Fecher, Leslie A, Flaherty, Keith T, Gershenwald, Jeffrey E, Hamid, Omid, Hong, Angela, Kirkwood, John M, Lo, Serigne, Margolin, Kim, Messina, Jane, Postow, Michael A, Rizos, Helen, Ross, Merrick I, Rozeman, Elisa A, Saw, Robyn P M, Sondak, Vernon, Sullivan, Ryan J, Taube, Janis M, Thompson, John F, van de Wiel, Bart A, Eggermont, Alexander M, Davies, Michael A, Andrews, Miles C, Berry, Donald A, Block, Matthew S, Boland, Genevieve M, Bollin, Kathryn B, Carlino, Matteo S, Carvajal, Richard D, Cohen, Jonathan, Davar, Diwakar, Delman, Keith A, Dummer, Reinhard, Farwell, Michael D, Fisher, David E, Fusi, Alberto, Glitza, Isabella C, de Gruijl, Tanja D, Gyorki, David E, Hauschild, Axel, Hieken, Tina J, Larkin, James, Lawson, David H, Lebbe, Celeste, Lee, Jeffrey E, Lowe, Michael C, Luke, Jason J, McArthur, Grant A, McDermott, David F, McQuade, Jennifer L, Mitchell, Tara C, Petrella, Teresa M, Prieto, Peter A, Puzanov, Igor, Robert, Caroline, Salama, April K, Sandhu, Shaneen, Schadendorf, Dirk, Shoushtari, Alexander N, Sosman, Jeffrey A, Swetter, Susan M, Tanabe, Ken K, Turajlic, Samra, Tyler, Douglas S, Woodman, Scott E, Wright, Frances C, Zager, Jonathan S, Ascierto, Paolo A, Spillane, Andrew J, van Akkooi, Alexander C J, Wargo, Jennifer A, Blank, Christian U, Tawbi, Hussein A, Long, Georgina V

“…Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to…”
Get full text